Amino Acid

Glucosamine and Chondroitin

Glucosamine (2-amino-2-deoxy-D-glucose), chondroitin sulfate

Evidence TierDWADA NOT PROHIBITED

tuneTypical Dose

900 MG to 3000 MG total combined daily

watchEffect Window

Short-term symptom change usually evaluated at 8-12 weeks. Structural endpoints measured over years.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Glucosamine and chondroitin are cartilage-related compounds used for joint pain and function goals. They are used mainly for osteoarthritis symptoms, with variable response across individuals.

Evidence suggests modest improvements in pain and function for knee osteoarthritis in some people, particularly with pharmaceutical-grade glucosamine sulfate. Some studies suggest slowed joint space narrowing, though results vary. Minority findings include benefits for temporomandibular joint discomfort and other musculoskeletal pain. Effects often require weeks of consistent use and are not universal.

Evidence favors cartilage-related pathway hypotheses, with limited and inconsistent clinical translation for pain/function.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Knee OA pain/function (WOMAC/KOOS-equivalent), rescue analgesic use

Secondary Outcomes

  • Structural progression surrogates (joint space narrowing)
  • chondroitin or combo symptom signals

Safety

Contraindications and Interactions

Contraindications

  • Shellfish allergy
  • Pregnancy/lactation without guidance
  • Severe renal/hepatic/bleeding risk

Side effects

  • Nausea
  • Diarrhea
  • Heartburn
  • Drowsiness

Interactions

  • Warfarin/anticoagulants
  • Multiple cartilage/NSAID overlaps

Avoid if

  • Active anticoagulation without specialist oversight
  • Unstable endocrine or kidney disease
  • Recent major GI bleed

Evidence

Study-level References

glucosamine-and-chondroitin-SRC-001Randomized, double-blind, placebo- and active-comparator controlled trial (GAIT)
Sourceopen_in_new

Clegg et al., NEJM, 2006, PMID: 16495392, DOI: 10.1056/NEJMoa052771

Population: Adults with symptomatic knee OA (approx. 1,500+ participants), multiple treatment arms over ~24 weeks

Key findings: No clinically important overall pain benefit vs placebo. Subgroup signal in moderate baseline pain group was small and not consistently durable.

Notes: Good internal trial methods, but multiple subgroup analyses and commercial product context reduce certainty of global effect.

Paper content

No clinically important overall pain benefit vs placebo; subgroup signal in moderate baseline pain group was small and not consistently durable

glucosamine-and-chondroitin-SRC-002Network meta-analysis / pooled randomized evidence review
Sourceopen_in_new

Wandel et al., BMJ, 2010, PMID: 20847017, DOI: 10.1136/bmj.c4675

Population: Multiple OA pain trials across glucosamine and chondroitin preparations

Key findings: Average pain effects were small and below typical clinically important responder thresholds.

Notes: High heterogeneity, inconsistent dosing/diagnosis definitions, and variable trial quality.

Paper content

Average pain effects were small and below typical clinically important responder thresholds

glucosamine-and-chondroitin-SRC-003Randomized, long-duration, placebo-controlled clinical trial
Sourceopen_in_new

Reginster et al., Lancet, 2001, PMID: 11214126, DOI: 10.1016/S0140-6736(00)03610-2

Population: Mild-to-moderate knee OA adults, ~3-year follow-up

Key findings: Structural signal (joint space narrowing) favored glucosamine sulfate versus placebo. Pain/function findings were modest and mixed.

Notes: Older protocol and limited external replication. Structural endpoint surrogate for function.

Paper content

Structural signal (joint space narrowing) favored glucosamine sulfate versus placebo; pain/function findings were modest and mixed

glucosamine-and-chondroitin-SRC-004Systematic review and meta-analysis
Sourceopen_in_new

Towheed et al., Cochrane Review of chondroitin/related compounds, 2015 update, PMID: 25629804, DOI: 10.1002/14651858.CD005614.pub2

Population: Chondroitin and combination RCTs in OA, mixed joint sites/formulations

Key findings: Some small pain/function improvements, but certainty and consistency are low.

Notes: Evidence quality downgraded for small-study effects and reporting bias.

Paper content

Some small pain/function improvements, but certainty and consistency are low

glucosamine-and-chondroitin-SRC-005Evidence-based clinical practice guideline
Sourceopen_in_new

ACR/Arthritis Foundation OA guideline, 2020, PMID: 31908149, DOI: 10.1002/acr.24131; OARSI guidance: https://www.rheumatology.org/Portals/0/Files/OARSI-2019-guideline.pdf

Population: Broad OA guideline panel across adults with knee/hip OA

Key findings: Does not strongly support glucosamine/chondroitin as core therapy. Generally places them low priority vs established non-pharmacologic and analgesic strategies.

Notes: Guideline quality is high, but recommendations reflect uncertainty and variable patient preference.

Paper content

Does not strongly support glucosamine/chondroitin as core therapy; generally places them low priority vs established non-pharmacologic and analgesic strategies

glucosamine-and-chondroitin-SRC-006Regulatory policy listing
Sourceopen_in_new

WADA Prohibited List, 2026 edition, https://www.wada-ama.org/en/prohibited-list

Population: Global anti-doping compliance reference

Key findings: No explicit prohibition of glucosamine/chondroitin as of listed source, but absence from list is not a clinical or safety endorsement.

Notes: Policy can change quickly. Enforcement depends on supplement contamination controls and sport/event updates.

Paper content

No explicit prohibition of glucosamine/chondroitin as of listed source, but absence from list is not a clinical or safety endorsement

glucosamine-and-chondroitin-SRC-007Systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_new

Park YB, Kim JH. Effectiveness and Safety of SYSADOAs Used in Eastern and Western Regions for the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2025;61(2):331. doi:10.3390/medicina61020331. PMID:40005447.

Population: Patients with knee osteoarthritis across included RCTs.

Dose protocol: Systematic review and meta-analysis of SYSADOAs (glucosamine sulfate, chondroitin sulfate, plant extracts) for knee OA.

Key findings: Pain improvement versus placebo at both early (SMD 0.38) and later (SMD 0.22) timepoints. No significant difference versus non-placebo comparators. Safety comparable to controls.

Notes: Supports non-inferiority to pharmacologic drugs but not superiority. Small effect sizes consistent with the broader evidence pattern.

Paper content

This 2025 systematic review and meta-analysis evaluated symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) including glucosamine sulfate, chondroitin sulfate, and plant extract formulations for knee OA. Pain improvement versus placebo was statistically significant at both early (SMD 0.38 within 3 months) and later (SMD 0.22 beyond 3 months) timepoints, though effect sizes were small. There was no significant difference between SYSADOAs and non-placebo comparators, and safety profiles were comparable. The results support non-inferiority to pharmacologic drugs but not superiority. The small effect sizes are consistent with the broader evidence pattern showing that glucosamine and chondroitin produce statistically significant but clinically modest benefits in knee OA.

glucosamine-and-chondroitin-SRC-008Bayesian network meta-analysis of RCTs with 12 months or more follow-up.
Sourceopen_in_new

Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018;320(24):2564-2579. doi:10.1001/jama.2018.19319. PMID:30575881.

Population: Patients with knee osteoarthritis from 47 RCTs.

Dose protocol: JAMA Bayesian network meta-analysis of 47 RCTs (22,037 patients) with 12 months or more follow-up.

Key findings: Glucosamine sulfate showed small long-term pain benefit (SMD -0.29) and strongest structural signal on joint space narrowing (SMD -0.42). Chondroitin sulfate showed smaller structural effect (SMD -0.20). Uncertainty around all pain estimates.

Notes: Industry-funded (Rottapharm Biotech). Long-term follow-up requirement is a strength, but sponsor involvement warrants cautious interpretation.

Paper content

This JAMA network meta-analysis pooled 47 RCTs (22,037 patients) with at least 12 months of follow-up to compare pharmacological treatments for knee OA. Glucosamine sulfate showed a small but statistically significant pain reduction (SMD -0.29) and the largest structural benefit on joint space narrowing (SMD -0.42). Chondroitin sulfate showed a smaller structural effect (SMD -0.20). However, the authors emphasized uncertainty around all pain effect estimates, and the structural benefits are surrogate endpoints whose clinical significance remains debated. The study is notable for requiring long-term follow-up (12 months or more), which filters out short-term trials and provides a more clinically relevant picture of sustained treatment effects. Glucosamine sulfate showed a more favorable profile than glucosamine hydrochloride.

Guides

Setup

Help